Cantor Fitzgerald Believes Pfizer (PFE) Still Has Room to Grow
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Pfizer (NYSE: PFE), with a price target of $45. The company’s shares closed on Friday at $44.91, close to its 52-week high of $45.
“We think respectable earnings growth, driven by IH and eventually EH, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, multiple expansion and upward earnings revisions should drive PFE shares higher, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $45.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 8.9% and a 41.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $46.91, representing a 4.5% upside. In a report issued on October 1, J.P. Morgan also maintained a Buy rating on the stock with a $46 price target.
See today’s analyst top recommended stocks >>
Pfizer’s market cap is currently $263.3B and has a P/E ratio of 12.04. The company has a Price to Book ratio of 3.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.